OpGen Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di OpGen.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Biotechs crescita degli utili	28.4%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Recent updates

OpGen to raise $3.38M in direct stock offering

Sep 30

OpGen's subsidiary signs R&D agreement with FIND

Sep 20

Nasdaq grants extension to OpGen to regain compliance with minimum bid price requirement

Aug 31

OpGen subsidiary Curetis and Annar ink Unyvero distribution partnership for Colombia

Jan 05

OpGen launches $10M private placement

Nov 24

OpGen EPS misses by $0.04, beats on revenue

Nov 11

OpGen's subsidiary and collaborators secures German funding to develop such a molecular diagnostics platform

Oct 28

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché OpGen non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

OTCPK:OPGN - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
9/30/2024	1	-10	-6	-6	N/A
6/30/2024	2	-22	-7	-6	N/A
3/31/2024	3	-27	-11	-10	N/A
12/31/2023	3	-33	-15	-14	N/A
9/30/2023	3	-26	-18	-17	N/A
6/30/2023	3	-36	-20	-18	N/A
3/31/2023	3	-36	-21	-20	N/A
12/31/2022	3	-37	-21	-20	N/A
9/30/2022	3	-41	-21	-20	N/A
6/30/2022	4	-33	-21	-21	N/A
3/31/2022	4	-34	-23	-22	N/A
12/31/2021	4	-42	-23	-21	N/A
9/30/2021	4	-35	-27	-25	N/A
6/30/2021	4	-37	-29	-27	N/A
3/31/2021	4	-37	-27	-26	N/A
12/31/2020	4	-26	-24	-23	N/A
9/30/2020	4	-22	-20	-20	N/A
6/30/2020	3	-17	-15	-15	N/A
3/31/2020	3	-13	-11	-11	N/A
12/31/2019	3	-12	-12	-12	N/A
9/30/2019	3	-14	-11	-11	N/A
6/30/2019	3	-13	-12	-11	N/A
3/31/2019	3	-14	-12	-12	N/A
12/31/2018	3	-13	-11	-11	N/A
9/30/2018	3	-13	-12	-11	N/A
6/30/2018	3	-13	N/A	-12	N/A
3/31/2018	3	-13	N/A	-12	N/A
12/31/2017	3	-15	N/A	-14	N/A
9/30/2017	3	-17	N/A	-16	N/A
6/30/2017	3	-19	N/A	-16	N/A
3/31/2017	4	-20	N/A	-18	N/A
12/31/2016	4	-19	N/A	-17	N/A
9/30/2016	4	-19	N/A	-16	N/A
6/30/2016	5	-19	N/A	-19	N/A
3/31/2016	4	-19	N/A	-16	N/A
12/31/2015	3	-18	N/A	-14	N/A
9/30/2015	3	-14	N/A	-13	N/A
6/30/2015	3	-12	N/A	-7	N/A
3/31/2015	4	-8	N/A	-6	N/A
12/31/2014	4	-6	N/A	-5	N/A
9/30/2014	4	-9	N/A	-5	N/A
12/31/2013	2	-16	N/A	-7	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista OPGN è superiore al tasso di risparmio ( 2.6% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di OPGN cresceranno più velocemente del mercato US

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di OPGN cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di OPGN cresceranno più rapidamente del mercato US.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di OPGN cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di OPGN è previsto essere elevato tra 3 anni

OpGen Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

OpGen, Inc. Announces Preliminary Unaudited Revenue for 2022

OpGen, Inc. Provides Revenue Guidance for Fiscal Year 2022

OpGen, Inc. Provides Earnings Guidance for the Year 2022

OpGen, Inc. Provides Revenue Guidance for the Year 2022

Recent updates

OpGen, Inc. announced delayed 10-Q filing

OpGen Receives a Letter from the Nasdaq Hearings Panel Determines to Deny its Request for Continued Listing on Nasdaq

OpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI Index

OpGen, Inc.(OTCPK:OPGN) dropped from NASDAQ Composite Index

OpGen, Inc. announced delayed 10-Q filing

OpGen Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on Nasdaq

Nasdaq Hearings Panel Grants Extension to OpGen, to Regain Compliance by July 8, 2024

OpGen Receives Notice from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5250(c)(1) Due to Not Filing its Quarterly Report on Form 10-Q for the Period Ended March 31, 2024

OpGen, Inc. announced delayed 10-Q filing

OpGen, Inc. Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Nasdaq Capital Market’s Minimum Bid Price Listing Requirement of $1.00 Per Share

OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K

OpGen, Inc. announced delayed annual 10-K filing

OpGen, Inc. announced delayed annual 10-K filing

Opgen, Inc. Announces Executive Changes

New major risk - Share price stability

New major risk - Revenue and earnings growth

OpGen Submits A Request for A Hearing Before the Panel, Which Request Stayed Any Suspension or Delisting Action by Nasdaq At Least Until the Hearing Process Concludes and Any Extension Granted by the Panel Expires

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

OpGen, Inc. announced that it expects to receive $1 million in funding

OpGen, Inc. announced that it expects to receive $1 million in funding

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

OpGen, Inc. to Report Q2, 2023 Results on Aug 10, 2023

OpGen Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement

First quarter 2023 earnings released: US$1.25 loss per share (vs US$2.93 loss in 1Q 2022)

OpGen, Inc. to Report Q1, 2023 Results on May 15, 2023

OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.

Full year 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

OpGen, Inc. Announces Preliminary Unaudited Revenue for 2022

OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million.

OpGen, Inc Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel

OpGen, Inc. Reports Goodwill Impairment Charge for the Third Quarter Ended September 30, 2022

OpGen, Inc. to Report Q3, 2022 Results on Nov 10, 2022

OpGen, Inc. to Report Q3, 2022 Results on Nov 10, 2022

OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $3.38 million.

OpGen, Inc. Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel

OpGen to raise $3.38M in direct stock offering

OpGen's subsidiary signs R&D agreement with FIND

Nasdaq Grants OpGen 180-Day Extension to Meet Minimum Bid Price Requirement

Nasdaq grants extension to OpGen to regain compliance with minimum bid price requirement

Opgen, Inc. Launches Ares Sequencing Services in the U.S. from Its Rockville, Maryland Laboratory

OpGen launches sequencing services for infectious diseases in US

OpGen, Inc. Provides Revenue Guidance for Fiscal Year 2022

OpGen GAAP EPS of -$0.13 beats by $0.02, revenue of $1M in-line

OpGen, Inc. to Report Q2, 2022 Results on Aug 11, 2022

OpGen reports preliminary revenue estimate for Q2 2022

OpGen, Inc. Announces Publication of Results of Unyvero Hospitalized Pneumonia (Hpn) Panel for Detection of Bacterial Respiratory Tract Pathogens from Serial Specimens Collected from Hospitalized Covid-19 Patients

OpGen, Inc. Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia Panel in the Lancet Respiratory Medicine

OpGen, Inc. Provides Earnings Guidance for the Year 2022

OpGen, Inc., Annual General Meeting, Jun 09, 2022

OpGen, Inc. Announces Interim Analysis Results from Clinical Trial for Unyvero Urinary Tract Infection Panel

OpGen, Inc. Provides Revenue Guidance for the Year 2022

OpGen, Inc. Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of Clinical Microbiology

OpGen gains on insider buying

OpGen, Inc. Submits Updated 510(k) Summary to FDA For Acuitas AMR Gene Panel for Isolates

OpGen submits 510(k) summary to FDA for Acuitas AMR Gene Panel for Isolates

OpGen, Inc. to Report Q4, 2020 Results on Mar 25, 2021

Evan Jones, Director of Opgen, Inc. Will Not Stand for Re-Election at the 2021 Annual Meeting of Stockholders

OpGen, Inc., Annual General Meeting, Jun 09, 2021

OpGen reports prelim Q4 & FY20 revenue

OpGen subsidiary Curetis and Annar ink Unyvero distribution partnership for Colombia

OpGen, Inc. Announces Results from 1,400 Patient Sample Multicenter Study Published: Unyvero LRT BAL Panel Provides Accurate Detection in Bronchoalveolar Lavage Fluid, Allowing Enhanced Diagnosis of Lower Respiratory Tract Infections

OpGen, Inc. announced that it expects to receive $10 million in funding

OpGen launches $10M private placement

OpGen EPS misses by $0.04, beats on revenue

OpGen, Inc. to Report Q3, 2020 Results on Nov 11, 2020

OpGen's subsidiary and collaborators secures German funding to develop such a molecular diagnostics platform

OpGen, Inc. Demonstrates the Clinical Utility of Unyvero LRT Panel and Its Potential Impact on Antibiotic Use in Hospitalized Patients with Suspected Pneumonia

OpGen, Inc. Announces Successful Completion of Study Collaboration with Karolinska Institutet on Bacterial Co-Infections in Covid-19 Pneumonia Patients and Presents Data on Unyvero Hpn Panel At Eccvid 2020

Previsioni di crescita degli utili e dei ricavi